PBE

Invesco Dynamic Biotechnology & Genome ETF
*Unless otherwise stated, data provided by FactSet.

PBE Fund Description

PBE tracks a tiered equal-weighted index of companies principally engaged in biotechnology and genetic engineering.

PBE Factset Analytics Insight

PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the fund’s portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February.

PBE MSCI ESG Analytics Insight

Invesco Dynamic Biotechnology & Genome ETF has an MSCI ESG Fund Rating of BBB based on a score of 5.56 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Invesco Dynamic Biotechnology & Genome ETF ranks in the 39th percentile within its peer group and in the 69th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

PBE MSCI FaCS and Factor Box

MSCI FaCS is a standard method for evaluating and reporting the Factor characteristics of equity portfolios including ETFs. The Factor Box includes 6 Factors that MSCI has identified that historically provided a return premium. On the vertical axis, the Factor Groups, are displayed and the horizontal axis displays the Factor exposure, overweight, underweight or neutral.

PERFORMANCE [as of 06/10/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
PBE 6.17% 4.77% 8.63% 34.59% 12.54% 14.28% 13.45%
PBE (NAV) 11.33% 6.98% 10.24% 36.84% 13.02% 15.09% 13.89%
Dynamic Biotechnology & Genome Intellidex Index 11.39% 7.14% 10.51% 37.66% 13.63% 15.44% 14.23%
Thomson Reuters US Biotechnology & Medical Research 11.04% 7.58% 6.29% 21.21% 16.11% 15.37% 21.00%
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

PBE Summary Data

Invesco
06/23/05
Open-Ended Fund
0.58%
$290.67M
$535.73K
0.22%

PBE Portfolio Data

$19.46B
157.11
5.54
0.04%
06/21/21
29

PBE Index Data

Tiered
Multi-Factor
Thomson Reuters US Biotechnology & Medical Research

PBE Portfolio Management

0.58%
-0.85%
-0.59%
-1.90%

PBE Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

PBE Fund Structure

Open-Ended Fund
No
Yes
-- / --
N/A
N/A
Low
Daily

PBE Factset Analytics Block Liquidity

As of 06/11/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of PBE. PBE is rated a 5 out of 5.

PBE Tradability

7,282
$535.73K
5,863
$411.89K
0.22%
$0.16
-0.01%
0.55% / -0.26%
None
94.00%
50,000
0.12
0.00%
0.39%
0
$77.31
5

PBE Sector/Industry Breakdown


PBE
Segment Benchmark
31.60%
42.10%
16.38%
45.20%
15.35%
0.45%
14.60%
--
9.18%
--
5.04%
7.04%
2.88%
--

PBE Top 10 Holdings[View All]

Biogen Inc. 7.04%
Catalent Inc 4.89%
Amgen Inc. 4.69%
4.57%
Alkermes Plc 2.95%
46.95%

PBE Countries


PBE
Segment Benchmark
100.00%
100.00%

PBE Regions


PBE
Segment Benchmark
100.00%
100.00%

PBE Economic Development


PBE
Segment Benchmark
100.00%
100.00%

PBE Performance Statistics

0.83
1.03
1.01
1.04
0.73%
Thomson Reuters US Biotechnology & Medical Research

PBE MSCI ESG Ratings

5.56 / 10
68.64
38.53
--
23.74%
25.75

PBE Benchmark Comparison Holdings

29
263
16
11.34%

PBE Benchmark Comparison Summary


PBE
Segment Benchmark
29
263
$19.46B
$28.45B
157.11
-37.53
5.54
6.34
0.17%
0.40%
Medium
Medium

PBE Benchmark Comparison Market Cap Size


PBE
Segment Benchmark
37.40%
54.25%
39.35%
26.59%
23.26%
16.39%
0.00%
2.76%